Die Bedeutung von GABAA-Rezeptoren für Pathophysiologie und Therapie der Panikstörung

American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington DC American Psychiatric Association (1998) Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 155:1–34 Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC (1999) Outer retinal dysfunction in patients treated with vigabatrin. Neurology 52:1201–1205 Ballenger JC, Burrows GD, DuPont RL,Jr et al. (1988) Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. I. Efficacy in short-term treatment. Arch Gen Psychiatry 45:413–422 Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J (2002) Guidelines for the pharmacological treatment of anxiety and obsessive-compulsive disorders. World J Biol Psychiatry 3:171–199 Barlow DH (1997) Cognitive-behavioral therapy for panic disorder: current status. J Clin Psychiatry 58:32–36 Boerner RJ, Möller H-J (1996) Pharmakotherapie der Panikstörung und/oder Agoraphobie. Psychopharmakotherapie 3:168–177 Carter RB, Wood PL, Wieland S et al. (1997) Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3-methyl-5α-pregnan-20-one), a selective high-affinity steroid modulator of the GABAA receptor. J Pharmacol Exp Ther 280:1284–1295 Changeux J-P, Devillers-Thiery A, Galzi J-L, Bertrand D (1992) New mutants to explore nicotinic receptor functions. Trends Pharmacol Sci 13:299–301 Collins I, Moyes C, Davey WB et al. (2002) 3-Heteroaryl-2-pyridones: benzodiazepine site ligands with functional selectivity for alpha 2/alpha 3-subtypes of human GABA(A) receptor-ion channels. J Med Chem 45:1887–1900 Crestani F, Löw K, Keist R, Mandelli M, Möhler H, Rudolph U (2001) Molecular targets for the myorelaxant action of diazepam. Mol Pharmacol 59:442–445 Crestani F, Martin JR, Möhler H, Rudolph U (2000) Resolving differences in GABAA receptor mutant mouse studies. Nat Neurosci 3:1059 Cross-national collaborative panic study. Second phase investigators (1992) Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 160:191–202 Damianisch K, Rupprecht R, Lancel M (2001) The influence of subchronic administration of the neurosteroid allopregnanolone on sleep in the rat. Neuropsychopharmacology 25:576–584 Eke T, Talbot JF, Lawden MC (1997) Severe persistent visual field constriction associated with vigabatrin. Br Med J 314:180–181 Faulhaber J, Steiger A, Lancel M (1997) The GABAA agonist THIP produces slow wave sleep and reduces spindling activity in NREM sleep in humans. Psychopharmcology 130:285–291 Gasior M, Carter RB, Witkin JM (1999) Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol Sci 20:107–112 Gee KW, McCauley LD, Lan NC (1995) A putative receptor for neurosteroids on the GABAA receptor complex: the pharmacological properties and therapeutic potential of epalons. Crit Rev Neurobiol 9:207–227 Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OAC, Charney DS, Krystal JH (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. Arch Gen Psychiatry 58:556–561 Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96:13512–13517 Hales TG, Lambert JJ (1992) Modulation of GABAA and glycine receptors by clomethiazole. Eur J Pharmacol 210:239–246 Hauser CAE, Wetzel CHR, Berning B, Gerner FM, Rupprecht R (1997) Flunitrazepam has an inverse agonistic effect on recombinant α6β2γ2 GABAA-receptors via a flunitrazepam-binding site. J Biol Chem 272:11723–11727 Hevers S, Lüddens H (1998) The diversity of GABAA receptors. Pharmacological and electrophysiologi cal properties of GABAA channel subtypes. Mol Neurobiol 18:35–86 Lambert JJ, Belelli D, Hill-Venning C, Peters JA (1995) Neurosteroids and GABAA receptor function. Trends Pharmacol Sci 16:295–303 Lancel M, Crönlein TAM, Faulhaber J (1996) Role of GABAA receptors in sleep regulation. Differential effects of muscimol and midazolam on sleep in rats. Neuropsychopharmacology 15:63–74 Lancel M, Faulhaber J, Deisz RA (1998) Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 123:1471–1477 Lancel M, Ruigt GSF, Deisz RA (1999) Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep 22:33–42 Leppik IE (1995) Tiagabine: the safety landscape. Epilepsia 36:10–13 Löw K, Crestani F, Keist R et al. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290:131–134 Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DN (1998) Decreased brain GABAA-benzodiazepine receptor binding in panic disorder. Arch Gen Psychiatry 55:715–720 Maricq AV, Peterson AS, Brake AJ, Myers RM, Julius D (1991) Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science 254:432–437 Mathias S, Wetter TC, Steiger A, Lancel M (2001) The GABA uptake inhibitor tiagabine promotes slow wave sleep in normal elderly subjects. Neurobiol Aging 22:247–253 Michelson LK, Marchione K (1991) Behavioral, cognitive, and pharmacological treatments of panic disorder with agoraphobia: critique and synthesis. J Consult Clin Psychol 59:100–114 Monaghan EP, McAuley JW, Data JL (1999) Ganaxolone: a novel positive allosteric modulator of the GABA(A) receptor complex for the treatment of epilepsy. Expert Opin Investig Drugs 8:1663–1671 Möhler H, Fritschy J-M, Rudolph U (2002) A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300:2–8 Nutt DJ, Glue P, Lawson C, Wilson S (1990) Flumazenil provocation of panic attacks: evidence for altered benzodiazepine receptor sensitivity in panic disorders. Arch Gen Psychiatry 47:917–925 Nutt DJ, Malizia AL (2001) New insights into the role of the GABAA-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390–396 Olsen RW, Tobin AJ (1990) Molecular biology of GABAA receptors. FASEB J 4:1469–1480 Paul SM, Purdy RH (1992) Neuroactive steroids. FASEB J 6:2311–2322. Puia G, Santi MR, Vicini S et al. (1990) Neurosteroids act on recombinant human GABAA receptors. Neuron 4:759–765 Romeo E, Ströhle A, Spalletta G et al. (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155:910–913 Roy-Byrne PP, Cowley DS, Greenblatt DJ (1990) Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47:534–538 Rudolph U, Crestani F, Benke D et al. (1999) Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes. Nature 401:796–797 Rudolph U, Crestani F, Möhler H (2001) GABAA receptor subtypes: dissecting their pharmacological functions. Trends Pharmacol Sci 22:188–194 Rupprecht R, Holsboer F (1999) Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 22:410–416 Rupprecht R, Holsboer F (2001) Neuroactive steroids in neuropsychopharmacology. Int Rev Neurobiol 46:461–477 Rupprecht R, Reul JMHM, Trapp T et al. (1993) Progesterone receptor-mediated effects of neuroactive steroids. Neuron 11:523–530 Sandford JJ, Forshall S, Bell C et al. (2001) Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol 15:205–208 Sayin Ü, Purali N, Özkan T, Altug T, Büyükdevrim S (1992) Vigabatrin has an anxiolytic effect in the elevated plus-maze test of anxiety. Pharmacol Biochem Behav 43:529–535 Schmitt U, Hiemke C (1999) Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 10:131–137 Schmitt U, Lüddens H, Hiemke C (2000) Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition. Pharmacol Biochem Behav 65:351–356 Shear MK, Weiner K (1997) Psychotherapy for panic disorder. J Clin Psychiatry 58:38–43 Sieghart W (1992) GABAA receptors: ligand-gated Cl-ion channels modulated by multiple drug-binding sites. Trends Pharmacol Sci 13:446–450 Sieghart W (2000) Unraveling the function of GABAA receptor subtypes. Trends Pharmacol Sci 21:411–413 Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K (1998) Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155:610–612 Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R (2002) GABAA receptor modulatory neuroactive steroid composition in panic disoder and during paroxetine treatment. Am J Psychiatry 159:145–147 Ströhle A, Romeo E, di Michele F et al. (2002) Induced panic attacks shift GABAA receptor modulatory steroid composition in patients with panic disorder: preliminary results. Archives of General Psychiatry (im Druck) Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95:3239–3244 Vanover KE, Rosenzweig-Lipson S, Hawkinson JE et al. (2000) Characterization of the anxiolytic properties of a novel neuroactive steroid, Co 2–6749 (GMA-839; WAY-141839; 3α, 21-Dihydroxy-3β-trifluoromethyl-19-nor-5β-pregnan-20-one), a selective modulator of γ-aminobutyric acidA receptors. J Pharmacol Exp Ther 295:337–345 Wieland HA, Lüddens H, Seeburg PH (1992) A single histidine in GABAA receptors is essential for benzodiazepine agonist binding. J Biol Chem 267:1426–1429 Wieland S, Belluzzi J, Hawkinson JE et al. (1997) Anxiolytic and anticonvulsant activity of a synthetic neuroactive steroid Co 3–0593. Psychopharmcol 134:46–54 Wisden W, Seeburg PH (1992) GABAA receptor channels: from subunits to functional entities. Curr Opin Neurobiol 2:263–269 Zwanzger P, Baghai T, Boerner RJ, Möller H-J, Rupprecht R (2001) Anxiolytic effects of vigabatrin in panic disorder. J Clin Psychopharmacol 21:539–540 Zwanzger P, Baghai TC, Schüle C, Minov C, Padberg F, Möller H-J, Rupprecht R (2001) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62:656–657 Zwanzger P, Baghai TC, Schüle C et al. (2001) Vigabatrin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology 25:699–703